Recent advances in the management of human immunodeficiency virus infection

Mayo Clinic Proceedings

Volumn 72, Issue 9, 1997, Pages 854-859

  Temesgen, Zelalem ^a   Wright, Alan J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

DRUG APPROVAL; DRUG CONTRAINDICATION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; NEPHROLITHIASIS; PRACTICE GUIDELINE; REVIEW; VIRUS PATHOGENESIS;

EID: 0030772468     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.9.854     Document Type: Review

References (25)

1. Pantaleo G, Graziösi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358
2. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-362
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123126
5. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122
6. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300
7. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong SJ, Stempien M, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:446454
8. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-579
9. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by quantity of virus in plasma. Science 1996;272:1167-1170
10. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis 1996;174:696703
11. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced HIV infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis 1996; 174:704-712
12. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoît S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N EnglJMed 1996;334:426-431
13. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologie and immunologie markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-1098
14. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-629
15. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-1421
16. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-153
17. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N EnglJMed 1996;335:1081-1090
18. Delta Coordinating Committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIVinfected individuals. Lancet 1996;348:283-291
19. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335:1099-1106
20. Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency withritonavir: update [abstract]. IntConfAIDS 1996;11:24
21. National Institutes of Health. Study confirms that combination treatment using a protease inhibitor can delay HIV disease progression and death [press release]. 1997 Feb 24
22. Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:19621969
23. Centers for Disease Control. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood-France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep 1995;44:929-933
24. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:11731180
25. Tumwesigye E, Loue S, Mortimer EA, Kambugu F, Whalen C. Changing prevalence of HIV infection and the clinical findings in women attending a Ugandan STD clinic [abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington (DC). 1997. p 98; abstract 181